Skip to main content

Table 2 Results from univariate survival analyses of aspirin intake and confounders on overall (OS), disease-free (DFS), and hematogenous metastasis-free (HMFS) survival

From: Effect of platelet inhibition with perioperative aspirin on survival in patients undergoing curative resection for pancreatic cancer: a propensity score matched analysis

Parameter

Median (meana) OS (95% CI) in months

3-YSR

5-YSR

Log-rank p

Median (meana) DFS (95% CI) in months

Log-rank p

Median (meana) HMFS (95% CI) in months

Log-rank p

Pt. on aspirin

   

*0.006

 

*0.001

 

*0.005

 Yes

46.5a (35.6–57.4)

61.1%

61.1%

 

26.0 (16.7–35.3)

 

41.9a (30.3–53.4)

 

 No

24.6a (20.2–28.9)

26.3%

n/a

 

10.5 (6.5–14.5)

 

16.3 (11.4–21.1)

 

Age

   

0.405

 

0.348

 

0.957

 ≤ Median

26.5 (16.3–36.8)

40.9%

26.2%

 

14.5 (8.2–20.8)

 

17.9 (12.1–23.8)

 

 > Median

24.9 (14.8–34.9)

27.4%

n/a

 

13.5 (11.2–15.8)

 

21.5 (11.4–31.5)

 

Sex

   

0.555

 

0.856

 

0.949

 Female

24.2 (16.2–32.2)

29.2%

n/a

 

13.9 (11.7–16.1)

 

18.3 (7.3–29.4)

 

 Male

27.1 (17.3–37.0)

36.7%

21.4%

 

13.5 (8.5–18.5)

 

19.7 (14.4–24.9)

 

BMI

   

0.127

 

0.601

 

0.956

 ≤ Median

35.0 (19.4–50.6)

47.9%

28.9%

 

13.5 (6.7–20.3)

 

19.6 (13.6–25.7)

 

 > Median

21.0 (17.3–24.6)

40.3%

24.3%

 

13.9 (10.5–17.3)

 

17.7 (7.3–28.1)

 

ASA score

   

0.702

 

0.754

 

0.596

 ASA II

26.5 (17.7–35.4)

26.7%

n/a

 

14.5 (10.9–18.1)

 

14.5 (10.9–18.1)

 

 ASA III/IV

22.3 (14.4–30.2)

36.2%

21.2%

 

13.3 (9.7–16.9)

 

20.9 (12.7–29.0)

 

Platelet count

   

0.598

 

0.720

 

0.616

 Normal

24.2 (17.6–30.8)

34.0%

n/a

 

13.6 (11.0–16.2)

 

17.9 (11.4–24.4)

 

 < 150 G/l

21.0 (9.8–32.2)

n/a

n/a

 

9.0 (7.8–10.2)

 

23.9a (14.8–32.9)

 

 > 400 G/l

37.8 (0–81.7)

66,7%

n/a

 

19.7 (0.8–38.6)

 

19.7 (0.8–38.5)

 

Serum CA19-9

   

0.092

 

0.128

 

0.196

 ≤ Median

29.1 (19.3–38.8)

41.8%

n/a

 

15.5 (12.3–18.7)

 

26.0 (15.0–37.0)

 

 > Median

18.9 (11.3–26.5)

26.5%

21.2%

 

12.0 (7.0–17.0)

 

18.3 (10.7–25.9)

 

Type of resection

   

0.314

 

0.995

 

0.999

 PD

21.0 (17.7–24.2)

29.4%

21.5%

 

12.8 (9.3–16.3)

 

18.3 (9.2–27.4)

 

 DP

37.1 (21.6–52.6)

52.1%

n/a

 

16.2 (14.7–17.7)

 

20.9 (14.4–27.3)

 

 TP

26.5 (22.4–30.7)

30.0%

n/a

 

14.5 (7.3–21.7)

 

16.8 (12.1–21.4)

 

Tumor diameter

   

0.150

 

0.059

 

*0.032

 ≤ Median

27.0 (17.4–36.6)

41.7%

37.1%

 

13.9 (8.8–19.0)

 

27.0 (17.6–36.4)

 

 > Median

22.0 (13.4–30.6)

28.2%

n/a

 

12.8 (7.0–18.6)

 

16.2 (12.9–19.4)

 

T-stage

   

0.352

 

0.249

 

0.402

 T1/2

37.8 (13.6–62.0)

60.0%

30.0%

 

16.7 (12.5–20.9)

 

19.7 (12.8–26.5)

 

 T3

24.2 (17.4–31.0)

32.8%

n/a

 

13.3 (10.3–16.3)

 

17.9 (11.4–24.5)

 

Nodal stage

   

0.491

 

0.909

 

0.601

 N0

18.9 (13.9–23.9)

25.2%

25.2%

 

12.5 (9.1–15.9)

 

16.2 (8.1–24.2)

 

 N1

26.5 (21.2–31.8)

39.5%

n/a

 

13.6 (10.4–16.8)

 

18.3 (11.8–24.8)

 

ELN

   

0.120

 

0.103

 

0.540

 ≤ Median

21.8 (15.7–27.9)

28.6%

n/a

 

12.8 (9.0–16.6)

 

19.7 (14.3–25.0)

 

 > Median

27.1 (15.6–38.6)

40.6%

34.8%

 

14.9 (9.3–20.5)

 

17.7 (2.8–32.6)

 

Grading

   

0.840

 

0.713

 

0.240

 G1/2

35.0 (9.3–60.8)

41.0%

n/a

 

16.2 (12.1–20.3)

 

27.2 (12.4–41.9)

 

 G3

24.2 (18.3–30.1)

32.9%

24.0%

 

12.5 (9.0–16.0)

 

17.7 (11.6–23.8)

 

Lymphovasc. invas

   

*0.039

 

0.095

 

*0.049

 L0

27.4 (18.8–36.0)

42.1%

31.2%

 

16.3 (13.8–18.8)

 

26.0 (18.0–34.0)

 

 L1

18.9 (10.1–27.7)

24.6%

n/a

 

9.0 (7.2–10.8)

 

13.9 (8.6–19.2)

 

Vascular invasion

   

*0.039

 

**< 0.001

 

**< 0.001

 V0

27.0 (18.2–35.8)

38.7%

25.7%

 

16.3 (12.4–20.2)

 

24.9 (17.3–32.4)

 

 V1

14.4 (12.1–16.6)

16.3%

n/a

 

7.9 (6.4–9.4)

 

9.0 (4.5–13.6)

 

Perineural invasion

   

0.424

 

0.153

 

0.216

 Pn0

35.0 (11.1–58.9)

40.4%

20.2%

 

27.8 (11.9–43.7)

 

32.7 (17.4–48.0)

 

 Pn1

24.2 (17.2–31.2)

33.6%

n/a

 

13.3 (10.3–16.3)

 

17.7 (12.2–23.2)

 

R-status

   

0.366

 

0.756

 

0.225

 R0 wide

26.5 (18.3–34.8)

35.5%

24.3%

 

14.9 (11.2–18.6)

 

21.5 (11.4–31.5)

 

 R0 narrow

29.1 (15.8–42.3)

39.6%

n/a

 

13.9 (9.6–18.2)

 

17.9 (9.6–26.3)

 

 R1

18.9 (6.0–31.8)

26.7%

n/a

 

12.0 (4.6–19.4)

 

12.5 (1.2–23.7)

 

Add. venous resect

   

0.248

 

0.494

 

0.994

 Yes

17.6 (6.0–29.1)

25.0%

n/a

 

12.5 (6.3–18.7)

 

18.3 (9.3–27.4)

 

 No

27.1 (19.0–35.2)

38.7%

22.7%

 

13.9 (11.6–16.2)

 

19.7 (12.7–26.6)

 

Adjuvant therapy

   

0.010

 

0.634

 

0.672

 Yes

27.1 (14.2–40.1)

43.1%

n/a

 

15.5 (12.2–18.8)

 

19.7 (12.3–27.0)

 

 No unknown

12.4 (8.6–16.2)

19.3 (12.4–26.2)

n/a

26.9%

n/a

13.4%

 

8.3 (7.5–9.1)

12.8 (8.3–17.3)

 

21.5 (4.9–38.1)

 
  1. BMI body mass index, ASA American Society of Anesthesiologists Score, PD pancreaticoduodenectomy, DP distal pancreatectomy, total pancreatectomy; ELN examined lymph nodes
  2. aMedian could not be calculated due to too many censored cases, mean survival is presented; patients with missing data were excluded in univariate analyses for the respective parameter
  3. *p < 0.05, **p ≤ 0.001